Montelukast shows a success rate of 86.5% in improving allergic rhinitis symptoms when added to current asthma medication.
Montelukast Effectiveness: A Closer Look
The provided reference gives us insight into how effective montelukast can be when used in conjunction with existing asthma treatments. The study demonstrates a significant improvement in allergic rhinitis symptoms.
Results Breakdown
Here is a detailed breakdown of the results:
| Result Category | Percentage of Patients |
|---|---|
| Overall Improvement | 86.5% |
| "Very Good" Improvement | 37.7% |
| "Good" Improvement | 45.8% |
As you can see, a substantial majority of patients experienced improvements.
Key Takeaways
- High Success Rate: Montelukast, when added to existing asthma medications, resulted in an overall improvement in allergic rhinitis symptoms for 86.5% of the patients studied.
- Varied Improvement Levels: While most patients saw improvement, there were variations in the degree of improvement, with 37.7% reporting a "very good" improvement and 45.8% reporting a "good" improvement.
- Combined Therapy Benefits: The success of montelukast is highlighted when it's used as an additional therapy with existing asthma medications, suggesting it works well in a combined treatment approach.
In conclusion, based on the provided data, the success rate of montelukast for treating allergic rhinitis symptoms when combined with asthma medication is quite high, with 86.5% of patients experiencing improvement.
